Search: WFRF:(Link Brian K.)
> (2017) >
International Asses...
-
Maurer, Matthew J.Mayo Clinic Minnesota
(author)
International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma
- Article/chapterEnglish2017
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:777deb21-b323-4a82-a732-d2eb9702f9de
-
https://lup.lub.lu.se/record/777deb21-b323-4a82-a732-d2eb9702f9deURI
-
https://doi.org/10.1200/JCO.2017.73.8195DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:137317235URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Purpose Peripheral T-cell lymphomas (PTCLs) have aggressive clinical behavior. We have previously shown that event-free survival (EFS) at 24 months (EFS24) is a clinically useful end point in diffuse large B-cell lymphoma. Here, we assess EFS24 and subsequent overall survival (OS) in large, multinational PTCL cohorts. Patients and Methods Patients with systemic PTCL newly diagnosed from 2000 to 2012 and treated with curative intent were included from the United States and Sweden (initial cohorts) and from Canada (replication cohort). EFS was defined as time from date of diagnosis to progression after primary treatment, retreatment, or death. Subsequent OS was measured after achieving EFS24 or from the time of progression if it occurred within 24 months. OS rates were compared with the age-, sex-, and country-matched general population. Results Seven hundred seventy-five patients were included in the study (the median age at diagnosis was 64 years; 63% were men). Results were similar in the initial and replication cohorts, and a combined analysis was undertaken. Sixty-four percent of patients progressed within the first 24 months and had a median OS of only 4.9 months (5-year OS, 11%). In contrast, median OS after achieving EFS24 was not reached (5-year OS, 78%), although relapses within 5 years of achieving EFS24 occurred in 23% of patients. Superior outcomes after achieving EFS24 were observed in younger patients (≤ 60 years of age: 5-year OS, 91%). Conclusion EFS24 stratifies subsequent outcome in PTCL. Patients with PTCL with primary refractory disease or early relapse have extremely poor survival. However, more than one third of patients with PTCL remain in remission 2 years after diagnosis with encouraging subsequent OS, especially in younger patients. These marked differences in outcome suggest that EFS24 has utility for patient counseling, study design, and risk stratification in PTCL.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Ellin, FredrikLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lymphoma - Clinical Research,Lund University Research Groups(Swepub:lu)med-fke
(author)
-
Srour, Line
(author)
-
Jerkeman, MatsLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lymphoma - Clinical Research,Lund University Research Groups(Swepub:lu)onk-mje
(author)
-
Bennani, N. NoraMayo Clinic Minnesota
(author)
-
Connors, Joseph M.
(author)
-
Slack, Graham W.
(author)
-
Smedby, Karin E.Karolinska Institutet
(author)
-
Ansell, Stephen M.Mayo Clinic Minnesota
(author)
-
Link, Brian K.
(author)
-
Cerhan, James R.
(author)
-
Relander, ThomasLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lymphoma - Clinical Research,Lund University Research Groups(Swepub:lu)onk-tre
(author)
-
Savage, Kerry J.
(author)
-
Feldman, Andrew L.Mayo Clinic Minnesota
(author)
-
Mayo Clinic MinnesotaTumörmikromiljö
(creator_code:org_t)
Related titles
-
In:Journal of Clinical Oncology35:36, s. 4019-+0732-183X
-
In:Journal of clinical oncology : official journal of the American Society of Clinical Oncology35:36, s. 4019-+1527-7755
Internet link
Find in a library
To the university's database
- By the author/editor
-
Maurer, Matthew ...
-
Ellin, Fredrik
-
Srour, Line
-
Jerkeman, Mats
-
Bennani, N. Nora
-
Connors, Joseph ...
-
show more...
-
Slack, Graham W.
-
Smedby, Karin E.
-
Ansell, Stephen ...
-
Link, Brian K.
-
Cerhan, James R.
-
Relander, Thomas
-
Savage, Kerry J.
-
Feldman, Andrew ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Journal of Clini ...
-
Journal of clini ...
- By the university
-
Lund University
-
Karolinska Institutet